all news

OMT Announces New Antibody Discovery Program
Palo Alto, CA, July 9, 2012

Open Monoclonal Technology, Inc. (OMT) today announced an antibody discovery collaboration with Merck KGaA. OMT and Merck KGaA have entered into a collaboration whereby OMT will use its OmniRats™ to generate antibodies against several targets selected by Merck KGaA. Merck KGaA has the rights to further develop and commercialize the antibodies derived from the OmniRat™ as therapeutic and diagnostic products. Under the terms of the agreement, OMT will receive upfront payment, success-based milestones, and royalties.

"We are pleased to be collaborating with Merck KGaA. OMT's OmniRat™ generates antibodies with great specificity, affinity and manufacturability. Our partners are looking for technologies that can eliminate time-consuming humanization of antibodies or optimization of leads identified using display technology. The OmniRat™ can save significant development time and is available for all targets", said Roland Buelow, Founder and CEO of OMT.

About Open Monoclonal Technology, Inc. (OMT) Open Monoclonal Technology, Inc. (“OMT”) is a private biotechnology company that is the first to develop a fully human monoclonal antibody platform based on transgenic rats. The rat is a widely used laboratory animal with a well-characterized immune system, a nearly complete genome sequence, and established transgenesis and hybridoma technologies. OMT’s OmniRat™ antibody platform results from an improved understanding of B-cell development and a novel approach to the inactivation of endogenous antibody expression. Up until now, the mouse was the only genetically engineered animal commercially available for human monoclonal antibody production. With OmniRat™, OMT has introduced a new proprietary technology platform with unrestricted development options for fully human monoclonal antibodies. The technology is patent protected and has broad freedom to operate.


Please visit:
Open Monoclonal Technology, Inc. (OMT)

or contact:
Dr. Roland Buelow
Tel: +1-650-224-6835